DADC
NYMX

D.A. Davidson & Co’s Nymox Pharmaceutical Corp NYMX Stock Holding History

D.A. Davidson & Co’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200
Closed – – 2305
2015
Q3 		$0 Buy
+200
New +$465 ﹤0.01% 2311

Other funds holding NYMX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

D.A. Davidson & Co's NYMX Position: Q4 2015 in Review

D.A. Davidson & Co sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2015, closing a stake of 200 shares.

D.A. Davidson & Co first reported a position in NYMX in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 31 funds tracked by Wall St. Rank hold NYMX as of Q4 2015.

  • D.A. Davidson & Co reported no remaining Nymox Pharmaceutical Corp position as of Q4 2015 after selling out during the quarter.
  • D.A. Davidson & Co sold 200 Nymox Pharmaceutical Corp shares in Q4 2015.
  • D.A. Davidson & Co first reported a position in Nymox Pharmaceutical Corp in Q3 2015 and held it in 1 quarter.
  • D.A. Davidson & Co's Nymox Pharmaceutical Corp position peaked at $0 in Q3 2015.
  • 31 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2015.

Based on D.A. Davidson & Co's 13F filing for Q4 2015, filed 12 Feb 2016.